We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific ((BSX - Free Report) ) manufactures medical devices and products used in various interventional medical specialties worldwide, including cardiovascular and surgical categories.
On July 29, BSX reported revenue of $5.44 billion for their June quarter, up 7.5% over the same period last year. EPS came in at $0.86, compared to $0.75 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $5.38 billion, representing a surprise of +1.07%. The company delivered an EPS surprise of +3.61%, with the consensus EPS estimate being $0.83.
In response to the conference call and management's lowered guidance, analysts notched down their EPS estimates for this year and next, causing BSX shares to fall into the cellar of the Zacks Rank.
Since its 2025 highs near $110, BSX has been in a steady bear market, making new 52-week lows above $42 last month -- despite nearly doubling revenues in the last 5 years to cross $21 billion.
The stock may soon sort out a bottom after this report given other strong metrics under the hood of the business which continues to grow the top and bottom lines at mid-single digits.
Key Metrics Versus Estimates
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenue- Rest of the World: $2.02 billion compared to the $1.98 billion average estimate based on two analysts. The reported number represents a change of +9.8% year over year.
Geographic Revenue- U.S.: $3.43 billion versus $3.39 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change.
Net Sales- MedSurg- Worldwide: $1.82 billion compared to the $1.8 billion average estimate based on five analysts. The reported number represents a change of +5.9% year over year.
Net Sales- Cardiovascular- Worldwide: $3.62 billion versus $3.6 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8.3% change.
Net Sales- MedSurg- Neuromodulation- Worldwide: $341 million versus $335.33 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.5% change.
Net Sales- MedSurg- Endoscopy- Worldwide: $793 million versus $774.1 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.6% change.
Net Sales- MedSurg- Urology- Worldwide: $684 million compared to the $694.74 million average estimate based on four analysts. The reported number represents a change of +1.2% year over year.
Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide: $585 million compared to the $601.79 million average estimate based on three analysts. The reported number represents a change of -0.9% year over year.
Net Sales- Cardiovascular- Interventional Cardiology & Vascular Therapies- Worldwide: $1.33 billion compared to the $1.26 billion average estimate based on three analysts. The reported number represents a change of +82.4% year over year.
Net Sales- Cardiovascular- Watchman- Worldwide: $507 million compared to the $535.88 million average estimate based on three analysts. The reported number represents a change of +4.3% year over year.
Net Sales- Cardiovascular- Electrophysiology- Worldwide: $916 million versus $923.15 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.
Bottom line: Investors may be looking for the next innovation or acquisition from BSX that could get growth closer to double-digits. Until then, accumulating shares under $50 and near 3X sales might offer long-term upside given these solid MedTech segments.
View the Zacks #1 Rank List
Image: Bigstock
Bear of the Day: Boston Scientific (BSX)
Boston Scientific ((BSX - Free Report) ) manufactures medical devices and products used in various interventional medical specialties worldwide, including cardiovascular and surgical categories.
On July 29, BSX reported revenue of $5.44 billion for their June quarter, up 7.5% over the same period last year. EPS came in at $0.86, compared to $0.75 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $5.38 billion, representing a surprise of +1.07%. The company delivered an EPS surprise of +3.61%, with the consensus EPS estimate being $0.83.
In response to the conference call and management's lowered guidance, analysts notched down their EPS estimates for this year and next, causing BSX shares to fall into the cellar of the Zacks Rank.
Since its 2025 highs near $110, BSX has been in a steady bear market, making new 52-week lows above $42 last month -- despite nearly doubling revenues in the last 5 years to cross $21 billion.
The stock may soon sort out a bottom after this report given other strong metrics under the hood of the business which continues to grow the top and bottom lines at mid-single digits.
Key Metrics Versus Estimates
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenue- Rest of the World: $2.02 billion compared to the $1.98 billion average estimate based on two analysts. The reported number represents a change of +9.8% year over year.
Geographic Revenue- U.S.: $3.43 billion versus $3.39 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change.
Net Sales- MedSurg- Worldwide: $1.82 billion compared to the $1.8 billion average estimate based on five analysts. The reported number represents a change of +5.9% year over year.
Net Sales- Cardiovascular- Worldwide: $3.62 billion versus $3.6 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8.3% change.
Net Sales- MedSurg- Neuromodulation- Worldwide: $341 million versus $335.33 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.5% change.
Net Sales- MedSurg- Endoscopy- Worldwide: $793 million versus $774.1 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.6% change.
Net Sales- MedSurg- Urology- Worldwide: $684 million compared to the $694.74 million average estimate based on four analysts. The reported number represents a change of +1.2% year over year.
Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide: $585 million compared to the $601.79 million average estimate based on three analysts. The reported number represents a change of -0.9% year over year.
Net Sales- Cardiovascular- Interventional Cardiology & Vascular Therapies- Worldwide: $1.33 billion compared to the $1.26 billion average estimate based on three analysts. The reported number represents a change of +82.4% year over year.
Net Sales- Cardiovascular- Watchman- Worldwide: $507 million compared to the $535.88 million average estimate based on three analysts. The reported number represents a change of +4.3% year over year.
Net Sales- Cardiovascular- Electrophysiology- Worldwide: $916 million versus $923.15 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.
Boston Scientific targets $500M run-rate savings and cites seven major launches by 2028. For more on that and reactions to the quarter, see this article: BSX Q2 Earnings Call Highlights WATCHMAN and EP Pressure
Bottom line: Investors may be looking for the next innovation or acquisition from BSX that could get growth closer to double-digits. Until then, accumulating shares under $50 and near 3X sales might offer long-term upside given these solid MedTech segments.